EMD Biosciences: R&D 100 Award-winning bacterial culture system is available from EMD Biosciences, Inc.


EMD Biosciences attends 2004 R&D 100 Award ceremony

MADISON, WI, December 7, 2004: EMD Biosciences, Inc. (www.emdbiosciences.com; EMD Biosciences), a major supplier of premium tools for proteomics and disease pathway analysis known through its global brands Calbiochem®, Novabiochem®, and Novagen®, today announced that F. William Studier, a biophysicist at Brookhaven National Laboratory (www.bnl.gov/world), received a 2004 R&D 100 award for developing an improved system for high-density growth of bacterial cells to produce recombinant proteins. EMD Biosciences is part of the Life Science and Analytics (LSA) division of Merck KGaA (www.merck.de; Darmstadt, Germany) and operates as EMD Biosciences, Inc. in North America and Merck Biosciences outside North America.

This culture system, marketed commercially through EMD Biosciences’ Novagen brand as the Overnight Express™ product line, does not require an inducing agent or constant monitoring of cell growth. Cultures grown with Overnight Express media can produce cell mass and protein yields up to 20 times greater than those produced with conventional induction methods, can use the entire range of growth temperatures, and can be used to express a broad range of proteins. One version is a defined medium used to produce high-levels of selenomethionine-labeled protein (e.g., for x-ray crystallography studies), which are difficult to obtain with conventional non-inducing media.

The newly introduced Overnight Express Instant TB Medium is a complete granulated culture medium available in two formats: EasyPak, an aluminum foil pouch containing 60 g of granulated medium sufficient for 1 L culture, and in 1 kg bottles. The granules ensure rapid and uniform dissolution in water and prevent clumping of the medium and inhalation of the airborne powder. To use, just add the granulated medium to water, supplement with glycerol, and microwave to dissolve.
“We are very pleased to make these media available to life science researchers,” commented Dr. Robert Mierendorf, Chief Technology Officer of EMD Biosciences. “To combine improved yield with a streamlined, time-saving technology will enable many scientists to achieve their research goals even more quickly. We were honored to stand with Dr. Studier at the award ceremony in Chicago, and look forward to continued successful collaborations.”

For further information, contact:

Alla Zilberman, Ph.D.
Director of Product Management
EMD Biosciences, Inc.
441 Charmany Drive
Madison, WI 53719-1234
United States of America
Tel: (608) 442-4033
Fax: (608) 238-1388
E-mail: [email protected]
Web: www.emdbiosciences.com

Diane Greenberg
BNL Media & Communications Office
Community, Education, Government & Public Affairs
Brookhaven National Laboratory
William Floyd Parkway, County Road 46
Upton, NY 11973
United States of America
Tel: (631) 344-2347
Fax: (631) 344-3368
E-mail: [email protected]
Web: www.bnl.gov

About EMD Biosciences, Inc.
EMD Biosciences, Inc. provides a broad range of innovative life science research products used world-wide in disease-related life science research at universities as well as in the pharmaceutical and biotech industry. The company is part of Merck KGaA’s Life Science and Analytics (LSA) division and operates as EMD Biosciences, Inc. in North America and Merck Biosciences outside North America. Globally, EMD Biosciences is known in the scientific community through its product brands Calbiochem®, Novabiochem®, and Novagen®.

About Merck KGaA
Merck is a global pharmaceutical and chemical company with sales of EUR 7.2 billion in 2003, a history that began in 1668, and a future shaped by 28,300 employees in 56 countries. Its success is characterized by innovations from entrepreneurial employees. Merck’s operating activities come under the umbrella of Merck KGaA, in which the Merck family holds a 74% interest and free shareholders own the remaining 26%. The former U.S. subsidiary, Merck & Co., has been completely independent of the Merck Group since 1917.

About Brookhaven National Laboratory
One of ten national laboratories overseen and primarily funded by the Office of Science of the U.S. Department of Energy (DOE), Brookhaven National Laboratory conducts research in the physical, biomedical, and environmental sciences, as well as in energy technologies and national security. Brookhaven Lab also builds and operates major scientific facilities available to university, industry, and government researchers. Brookhaven is operated and managed for DOE’s Office of Science by Brookhaven Science Associates, a limited-liability company founded by Stony Brook University, the largest academic user of Laboratory facilities, and Battelle, a nonprofit, applied science and technology organization.

Calbiochem, Novabiochem, and Novagen are registered trademarks and Overnight Express is a trademark of EMD Biosciences, Inc.